Science

Marwan Fakih: Meaningful clinical benefits for KRAS G12C MCRC

Marwan Fakih/X

Apr 14, 2025, 17:39

Marwan Fakih: Meaningful clinical benefits for KRAS G12C MCRC

Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared a post on X about a paper he co-authored with colleagues published in the Journal of Clinical Oncology:

“Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator’s Choice in Chemorefractory KRAS G12C Colorectal Cancer | Journal of Clinical Oncology.

Meaningful clinical benefits for KRAS G12C MCRC!”

“Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator’s Choice in Chemorefractory KRAS G12C Colorectal Cancer”

Authors: Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, David Paez Lopez-Bravo, Emily Chan, Joseph Chao, Qui Tran, Chiara Cremolini, Marwan Fakih et al.

Marwan Fakih: Meaningful clinical benefits for KRAS G12C MCRC

More posts featuring Marwan Fakih.

cancer Chiara Cremolini colorectal cancer David Paez Lopez-Bravo Dominik Paul Modest Emily Chan Filippo Pietrantonio Joseph Chao Journal of Clinical Oncology Lisa Salvatore Marwan Fakih mCRC OncoDaily Oncology Qui Tran Taito Esaki

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action